Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Medicine (Baltimore)
Main Authors: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Format: Artigo
Sprog:Inglês
Udgivet: Wolters Kluwer Health 2016
Fag:
5200
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://ncbi.nlm.nih.gov/pubmed/27495036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004330
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker